NOW PHARMAC FUNDED*

*From 1 March 2025, Vegzelma will be funded under special authority criteria for: recurrent respiratory papillomatosis, ocular conditions, unresectable hepatocellular carcinoma (liver cancer) and advanced ovarian cancer. By 1 August 2025, all people with recurrent respiratory papillomatosis will need to have transitioned to the Vegzelma brand of bevacizumab. For people with ocular conditions, ‘any brand’ of bevacizumab will continue to be funded in Health New Zealand | Te Whatu Ora hospitals.

THIS SITE IS DESIGNED FOR THE GENERAL PUBLIC IN NEW ZEALAND.

PRESCRIPTION MEDICINE. Vegzelma (bevacizumab biosimilar) is a prescription-only medicine containing bevacizumab. Vegzelma concentrate for solution for infusion is available as: (i) Vegzelma 100mg vial containing 4mL of bevacizumab and (ii) Vegzelma 400mg vial containing 16mL of bevacizumab (25mg/mL).

USES OF VEGZELMA. Vegzelma is prescribed for adult patients with: (i) metastatic colorectal cancer, (ii) advanced and/or metastatic renal cell cancer, (iii) advanced, metastatic or recurrent non-squamous non-small cell lung cancer, (iv) metastatic breast cancer, (v) relapsed high grade malignant glioma, (vi) epithelial ovarian, fallopian tube or primary peritoneal cancer, and/or (vii) cervical cancer.

RISKS AND BENEFITS. Vegzelma has risks and benefits. Always discuss your condition and treatment plan with your healthcare professional to determine if Vegzelma is right for you. If you have any specific questions about how Vegzelma might affect your treatment, side effects, or interactions with other medications, please seek their advice. If symptoms continue or you have side effects, see your doctor, pharmacist or healthcare professional. Normal doctor's charges apply.

NZ-VEG-25-00004. TAPS BG4934. Last updated April 2025.